Newsroom
IntelliGenome Receives FDA Breakthrough Device Designation for CRISPR-TB Blood Test
IntelliGenome, an innovative molecular diagnostic solutions provider, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its CRISPR-Tuberculosis (TB) Blood Test.
